Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma 1Leukemia 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Burkitt Lymphoma 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 1270Specimen Handling 921Magnetic Resonance Spectroscopy 832Carboplatin 829Cyclophosphamide 802Cisplatin 726Nivolumab 682Paclitaxel 639Radiotherapy 613Gemcitabine 578Biopsy 556Bevacizumab 477Dexamethasone 445fludarabine 405Docetaxel 382venetoclax 372Oxaliplatin 365Capecitabine 360Fluorouracil 358atezolizumab 345durvalumab 338Rituximab 336Drug Therapy 330Doxorubicin 319Radiosurgery 316Blood Specimen Collection 313Pemetrexed 308Standard of Care 306Ipilimumab 305Radiation 285

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
devimistat × 1 year × Clear all
NCT03793140 2026-03-27

A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
24 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoma

NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

University of Michigan Rogel Cancer Center

Phase 1/2 Terminated
75 enrolled 17 charts
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡